22.29
+0.22(+1.00%)
Currency In USD
| Previous Close | 22.07 |
| Open | 21.98 |
| Day High | 22.43 |
| Day Low | 21.39 |
| 52-Week High | 33.77 |
| 52-Week Low | 18.35 |
| Volume | 94,987 |
| Average Volume | 268,003 |
| Market Cap | 659.72M |
| PE | 3.09 |
| EPS | 7.22 |
| Moving Average 50 Days | 22.99 |
| Moving Average 200 Days | 25.55 |
| Change | 0.22 |
If you invested $1000 in Dianthus Therapeutics, Inc. (DNTH) since IPO date, it would be worth $95.95 as of February 05, 2025 at a share price of $22.29. Whereas If you bought $1000 worth of Dianthus Therapeutics, Inc. (DNTH) shares 5 years ago, it would be worth $108.67 as of February 05, 2025 at a share price of $22.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
GlobeNewswire Inc.
Jan 30, 2025 12:00 PM GMT
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimm
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2025 12:00 PM GMT
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimm
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
GlobeNewswire Inc.
Nov 07, 2024 9:01 PM GMT
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE’24 Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results antici